Imunon enters CRADA with NCI to advance IMNN-001 development
Imunon will work with the NCI Cancer Therapy Evaluation Program to evaluate IMNN-001 in new indications and combination regimens. Imunon retains ownership of its background intellectual property and can expand its IP through the collaboration.